Semaglutide, the medicine behind Ozempic and Wegovy, has been found to have significant benefits for heart health. Recent data from the largest and longest clinical trial on semaglutide use amongst those without diabetes, known as the Semaglutide and Cardiovascular Outcomes (SELECT) trial, has shown promising results. The study involved approximately 17,600 overweight or obese adults with pre-existing cardiovascular disease and was funded by Novo Nordisk, the drug manufacturer. Researchers discovered that weekly injections of semaglutide over a period of three years can reduce the risk of stroke, heart attack, or fatal cardiovascular events by nearly 20 percent on average.
A new study led by cardiologist John Deanfield from University College London has revealed that the benefits of semaglutide on cardiovascular health are not dependent on weight loss. Regardless of a participant’s starting weight or the amount of weight lost while on semaglutide, their risk of adverse cardiovascular events such as heart attacks or strokes still decreased by a similar percentage between 2018 and 2023. This finding is significant as it indicates that semaglutide’s positive impact on heart health goes beyond its role in inducing weight loss.
Recent analysis of the SELECT trial published in Nature Medicine has shown that sustained weight loss, averaging 10 percent over four years, was observed in individuals of various demographics. This substantial weight loss in a diverse population suggests that effective weight management with semaglutide could potentially reduce the burden of obesity-related illnesses. While the trial focused on cardiovascular events, the benefits of weight loss could extend to other chronic diseases such as cancer, osteoarthritis, anxiety, and depression.
Although semaglutide is well-known for its ability to suppress appetite and induce weight loss, its impact on cardiovascular health may involve mechanisms beyond treating obesity. The analysis by Deanfield, Ryan, and colleagues highlights the need for further research to understand the full range of health benefits associated with semaglutide. While the drug has shown promising results, there is still much to learn about its long-term effects on weight management and cardiovascular risks.
As researchers continue to investigate the effects of semaglutide on heart health and weight management, there are important considerations to keep in mind. While the drug has shown potential in reducing cardiovascular risks, it is essential to understand the mechanisms of action fully. The unexpected effects of semaglutide on heart health could potentially reshape our understanding of obesity and cardiovascular disease. Further studies are needed to determine the lasting impact of semaglutide treatment and its implications for public health.
Semaglutide holds promise for improving heart health beyond its role in weight loss. The findings from the SELECT trial and subsequent analyses underscore the need for continued research into the mechanisms of action of semaglutide and its potential benefits for individuals with and without diabetes. As we uncover more about the impact of semaglutide on cardiovascular health, we may be able to revolutionize the way we approach obesity and chronic diseases related to weight management.
Leave a Reply